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The aim of this study is to evaluate the properties of the Leg Activity measure according 
to COnsensus‐based Standards for the selection of health Measurement INstruments. 
Method 
Participants were assessed at baseline, one day, 6 weeks and 12 weeks, following 
treatment for leg spasticity with botulinum toxin and physical interventions. 
Results 
In stage 1, 64 participants were recruited to evaluate the initial psychometric properties 
of Leg Activity measure. In stage 2, 100 additional participants were recruited, to evaluate 
the scaling properties. Total sample of 164 participants was used.  
 
Construct validity was supported for ‘passive function’, ‘active function’ and ‘impact on 
quality of life’.  Cronbach’s alpha was 0.86, 0.97 and 0.87 respectively for the scales. 
Item level test-retest agreement ranged from 91-97% (Kappa 0.75-0.95). Following 
treatment for spasticity (n=64), the Leg Activity measure ‘passive function’ and ‘impact 
on life’ scales were responsive to change. 
 
Principal components analysis confirmed the constructs and a unidimensional Rasch 
Partial Credit Model was subsequently established for each scale. Transformation to an 
interval scale was achieved. Using the ordinal-to-interval conversion tables, parametric 
statistical analysis may be used.  
Conclusion 
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Spasticity is a common and distressing consequence of acquired brain injury, including 
stroke, trauma and other forms of brain injury.  It is estimated that up to one-third of 
post-stroke patients develop symptomatic spasticity [1, 2]  (overall range 4-42% [2, 3]), 
and approximately 75% of patients with physical disability following severe traumatic 
brain injury will develop spasticity requiring specific treatment.  Of these, 
approximately one-third may require treatment with botulinum toxin.  Spasticity 
interferes with leg movement and limits active functional tasks such as mobility and 
transfers, as well as increasing the burden on caregivers assisting people with personal 
care otherwise referred to as passive function [4].  Goals for treatment of leg spasticity 
often focus on active function improvements in walking, standing and transferring from 
different seated positions. However, improvements in passive function tasks and 
symptom management are often just as important to patients. Active function is the use 
of the limb to directly perform a task.  Passive function is the care of the affected limb, 
usually performed by the individual themselves, but may require assistance from 
another person [5]. 
 
There is a need for instruments with demonstrable measurement properties capable of 
reflecting clinically important change in practice.   Outcome measures developed for 
treatments such as botulinum toxin and physical interventions for spasticity aimed at 
improving any elements of functional performance (active and passive function), should 
ideally reflect function in real life, as opposed to just observed tasks in the clinic setting.  
Patient-reported measures offer this advantage and minimise the burden of data collection 
for clinicians in the clinical environment. 




Our systematic review of the published literature [6], identified a number of measures 
that addressed leg function (eight in total) using self-report by patients and carers. All the 
measures were designed for self-report by patients but some could also be completed by 
interview.  All the identified measures addressed active function (within the activity 
domain of the International Classification of Function, Disability and Health [7]). 
However, none addressed passive function – i.e. caring for the limb. A new self-report 
measure of active and passive function in the leg was therefore developed, the Leg 
Activity measure [8]. Conceptualisation and development of the Leg Activity measure 
has been published previously [8], in this paper we present the evaluation of its 
psychometric measurement properties.  
 
Outcome measures should be subject to evaluation confirming they provide a valid and 
reliable assessment of the clinical parameters in question and to allow understanding of 
their psychometric properties.  The COnsensus‐based Standards for the selection of health 
Measurement INstruments criteria provide a set of attributes against which the 
psychometric properties of health status and quality of life instruments may be judged [9-
11].  We aimed to use this framework to provide an evaluation of the psychometric 
properties of the Leg Activity measure. Criteria addressed in this initial analysis were; 
internal consistency, reliability, structural validity, interpretability, construct validity 
(hypothesis testing), responsiveness, and feasibility. 
 




At stage 1, initial psychometric evaluation was conducted in a cohort of participants, 
from three spasticity services. In stage 2, patients seen in routine practice for spasticity 
management were also recruited from one service.  
Sample Size Calculation 
The sample size was based on the criteria by Terwee and colleagues for evaluation of 
construct validity and test re-test reliability in groups of at least 50 participants [9] and 
recommendations by Sim and Wright for sample size in reliability studies [12]. This was 
applied to the recruitment of participants in stage 1. 
 
In stage 2 larger numbers of participants were required to enable more robust analysis 
using Principal Components Analysis and Rasch analysis resulting in an expanded cohort 
for these analyses. According to Lundgren-Nilsson and Tennant (2011) sample size 
should be a minimum 20 cases per item in the largest subscale for Rasch analysis (16,26).  
 
Stage 1: Subjects and setting 
The sample for stage 1 psychometric analysis was a prospective consecutive cohort of 
patients with lower limb spasticity presenting for treatment at one of three specialist 
spasticity services in London, UK between November 2014 and June 2016. Inclusion in 
the cohort study was based on a clinically identified need for spasticity management 
(including botulinum toxin injection) as part of a rehabilitation programme. Services were 
chosen purposively to reflect the range/types of specialist spasticity services available in 
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the UK, but with relevance more widely to other countries and health systems. The 
services were:  
1. An academic regional rehabilitation service, with associated outreach (to 
other rehabilitation units, community and referring hospitals) and spasticity 
service. 
2. A local specialist rehabilitation service with associated spasticity clinic. 
3. A regional spasticity service based at a tertiary hospital. 
The services represent the current range of services offering spasticity management in 
the context of rehabilitation in the UK. 
 
The cohort was assessed at baseline (Time 1) and one day later (Time 2), for the 
evaluation of repeatability, and then at 6 weeks (Time 3) and 12 weeks (Time 4), 
following treatment for leg spasticity with Botulinum toxin and physical interventions.   
 
Patients included were adults aged between 18 and 85 years with primarily a hemiplegic 
presentation and leg spasticity impacting either active or passive function. Patients were 
excluded if they declined to participate or if their family and/or treating team declined on 
their behalf; or if they were unable to complete a questionnaire and no carer (professional 
or family) was available to undertake questionnaire completion on their behalf.   
 
Stage 2: Subjects and setting 
The additional sample for stage 2 analysis was a prospective consecutive, routinely 
collected, cohort of patients with lower limb spasticity presenting for treatment at one 
specialist spasticity service in London, UK between June 2016 and March 2018. Inclusion 
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in the cohort study was based on a clinically identified need for spasticity management 
(including botulinum toxin injection) as part of a rehabilitation programme.  
 
The cohort was assessed at baseline (Time 1). Patients included were adults aged between 
18 and 85 years with primarily a hemiplegic presentation and leg spasticity impacting 
either active or passive function. All participants underwent treatment for spasticity 
requiring Botulinum toxin intervention and physical interventions.  Patients were 
excluded if they declined to participate or if their family and/or treating team declined on 
their behalf; or if they were unable to complete a questionnaire and no carer (professional 
or family) was available to undertake questionnaire completion on their behalf.   
 
Measures  
Measures in this study were used to support psychometric evaluation of Leg Activity 
measure. The Leg Activity measure, Rivermead Mobility Index and Euro Quality of life 
5 Dimensions were used to rate function by patients on the basis of activities performed 
over the preceding seven days. The Modified Ashworth Scale is used to rate spasticity 
and Goal Attainment Scaling is used to measure goal outcome. 
• The Leg Activity measure [8] is a patient or carer-rated 33-item measure of 
difficulty in passive and active leg function, as well as spasticity related quality-
of-life (symptoms and participatory impact).  It comprises a nine-item Passive 
function subscale, a fifteen-item Active function subscale and a nine-item 
symptoms and impact on quality-of-life subscale, and uses a Likert scoring system 
between 0 (No difficulty) and 4 (unable to do task).  The Passive function scale 
scores range from 0 (high function) to 36 (no function), Active function scale 
Psychometric evaluation the Leg Activity measure 
 
 11 
scores from 0 (high function) to 60 (no function) and Symptoms and Impact scale 
from 0 (high function) to 36 (no function). The Leg Activity measure is freely 
available to use and can be obtained with full instructions for completion, from 
the King’s College London, Department of Palliative Care, Policy and 
Rehabilitation web site:  
https://www.kcl.ac.uk/lsm/research/divisions/cicelysaunders/attachments/LEG 
ACTIVITY MEASURE.pdf . 
 
• The Rivermead Mobility Index [13-16] is a fifteen item measure of mobility 
(active) function items in a hierarchical order with increasing item difficulty.   
Items are dichotomous with a yes / no response option. The Rivermead Mobility 
Index was used as a comparison measure with Leg Activity measure for the active 
function scale. 
 
• The Euro Quality of life 5 Dimensions [17] is a five item questionnaire with a 
further vertical scale on general health, scored from 0 (worst health) to 100 (best 
health). The five items are each scored on a five-point scale from ‘no health 
limitation’ to the ‘most extreme health limitation’.  The Euro Quality of life 5 
Dimensions was used as a comparison measure with Leg Activity measure for the 
impact on quality of life scale. 
 
• The feasibility questionnaire was used to evaluate ease of use, relevance and 
value in the clinical situation for the Leg Activity measure.  It comprises one 
question each for a) time to complete, b) relevance and c) ease of completion.  
Psychometric evaluation the Leg Activity measure 
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Each question is rated on a 5-point Likert scale (e.g. for ease of completion: Very 
easy, Easy, Moderate, Difficult, Very difficult). 
 
• The Modified Ashworth Scale [18, 19] is a clinical measure of spasticity which  
forms a single item scale from 0 (no increase in muscle tone) to 4 (affected part 
rigid in flexion or extension), with an additional point at +1 (slight increase in 
muscle tone) producing a six-point scale.  The Modified Ashworth Scale therefore 
provides a single score to represent spasticity. Modified Ashworth Scale was 
scored for the relevant joint or joints and used as a comparison measure with the 
Leg Activity measure scales. 
 
• Goal Attainment Scaling [20] is a method of evaluating the extent to which 
patient’s individual goals are achieved in the course of intervention.  Scoring of 
Goal Attainment Scaling followed the approach proposed by Turner-Stokes [21], 
but was used in this study to identify ‘responders’ and ‘non responders’ to 
treatment for spasticity without calculation of the ‘T’ score. Patients were 
categorised as responders if they achieved a score of 0 to +2 for their primary 
treatment goal, and non-responders if they achieved a score of -1 to -2 [20, 21]. 
Goal Attainment Scaling was also used as a comparison with the different scales 
of Leg Activity measure when the primary goal category related to that scale. 
 
Goals were set prior to intervention using the Goal Attainment Scaling method for 
negotiating and recording goals [20, 21].  The Leg Activity measure, Rivermead Mobility 
Index, Euro Quality of life 5 Dimensions, Modified Ashworth Scale and feasibility 
questionnaire were recorded at baseline.  The Leg Activity measure was repeated one day 
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later to enable the evaluation of test-retest reliability.  Measures were then repeated at 6 
weeks and 12 weeks to enable the testing of responsiveness following intervention.   
 
Patients gave written informed consent (n=51).  For those patients unable to consent, 
consultation and approval was given by the next of kin (consultee) and the treating team 
(n=33) in accordance with the ethical approval received.  A cleaned, validated dataset 




Ethical approval for the research programme was received; National Research Ethics 
Service Committee London - South East (14/LO/1340). Participants gave their consent to 
involvement in this study. No personal or individual data are presented.  
 
Stage 1: Analysis  
Floor and ceiling effects were assessed in the study population by considering the 
percentage of participants at either extreme of the subscales according to the criteria by 
Terwee and colleagues [9]. 
 
Cronbach’s alpha (Time 1) was used to evaluate internal consistency. A positive rating 
for internal consistency was given when ratings for Cronbach’s alpha were between 0.70 
and 0.95 [9].   
 
Reproducibility (test re-test reliability) of Leg Activity measure was evaluated between 
Time 1 (Baseline) and Time 2 (one day later) using Quadratic Weighted Kappa 
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coefficients for test re-test reliability to comply with the recommendations of Terwee et 
al [9].   
 
Construct validity was established by evaluating hypotheses predicted for the three scales 
of Leg Activity measure when compared with other measures using the Spearman rank 
order correlation coefficient for convergent and divergent validity. 
• For the passive function scale it was hypothesised that change would be correlated 
with Goal Attainment Scaling ‘T’ score at 6 weeks. It was also hypothesised that 
Modified Ashworth Scale would be correlated with passive function at 6 weeks. 
• For active function it was hypothesised that it would be correlated with the 
Rivermead Mobility Index at 6 and 12 weeks. 
• For the impact scale it was hypothesised that Euro Quality of life 5 Dimensions 
would not be correlated due to its general quality-of-life focus and the very 
specific focus on spasticity related quality-of-life for the Leg Activity measure 
impact. However, it was hypothesised that it would be correlated with Modified 
Ashworth Scale at 6 and 12 weeks. 
 
Responsiveness of the Leg Activity measure was evaluated between baseline, 8 and 16 
weeks following Botulinum toxin-A injection.  Responsiveness was determined by 
comparing the change in Leg Activity measure between responder and non-responder 
groups using the non-parametric Mann-Whitney U test.  It was expected that the Leg 
Activity measure would identify a significant difference between the responder and the 
non-responder groups for passive function as defined by Modified Ashworth Scale and 
primary goal outcome (Goal Attainment Scaling) as a result of spasticity intervention.  A 
significant change was not expected in the group for active function, due the smaller 
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number of active function goals in this cohort, though some individuals were expected to 
make these changes [22, 23]. 
 
Stage 2: Analysis  
 
The unidimensionality of the three scales of the Leg Activity measure was initially 
examined using exploratory factor analysis and then Rasch analysis for confirmation of 
the structure and its scaling properties.  
Factor Analysis 
For exploratory factor analysis we used principal components analysis with Varimax 
rotation as these typically provide clear and interpretable solutions. All factor analyses 
were completed with IBM SPSS v.24 software. The Kaiser-Myer Olkin test and Bartlett’s 
Test of Sphericity were used to ensure that the correlation matrix was appropriate for 
factor analysis for each subscale. The decision as to how many components to rotate was 
based upon consideration of: (i) the number of components with eigenvalues > 1.0; 
inspection of the scree plot; and parallel analysis which compares the number of 
eigenvalues > 1.0 with the number expected by chance alone.  
 
Rasch Analysis 
For Rasch analysis we followed recommendations suggested by Lundgren-Nilsson and 
Tennant (2011) for improving the rigor of Rasch papers in the context of rehabilitation 
including the following: 
1. Use of the Andrich Rating Scale versus the Partial Credit Model chosen according 
to the Likelihood-Ratio test. The Rating Scale model assumes the distances 
between thresholds to be the same across all items whereas the Partial Credit 
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allows for flexibility. A significant Likelihood-Ratio test indicates the data are 
suitable for the Partial Credit Model. 
2. Examine several ‘analytical pathways’, including some with and without re-
ordering disordered thresholds. 
3. Creation of testlets or ‘super items’ to deal with local response dependency. Local 
dependency is identified by correlations in the residual (unexplained) variance 
among items.  Locally dependent items are simply summed or combined to form 
a super-item. 
4. Unidimensionality is tested using Rasch principal components analysis of the 
residuals and the equating test with paired t-tests across all participants. 
5. Where present, Differential Item Functioning might require splitting the sample 
according to the relevant person factor (e.g. age, sex, diagnostic group, etc.). 
6. Item removal only as a last resort (in order to maintain the clinical integrity of the 
instrument). 
7. Where possible, production of a transformation table to convert raw scores to 
Rasch-transformed scores, thus encouraging clinicians to use interval scores. 
We followed the above steps to deal with each of these issues, when they arose. We used 
the Likelihood-Ratio test, to determine whether the Rating Scale or Partial Credit Model 
for Rasch analysis was most appropriate. The summary statistics of the Rasch model were 
assessed based on the mean item and person location, individual item fit residual, the 
overall item-trait interaction chi-squared test/p value and the Person Separation Index 
(PSI), interpreted as follows: 
• The mean item location is always set to zero.  
• A mean person location (reflecting needs) of ±0.5 indicates a well-targeted scale.  
Psychometric evaluation the Leg Activity measure 
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• The overall mean values representing perfect fit for both item and person fit 
residual are 0.0 (SD=1).  
• The item-trait interaction chi square reflects the overall fit of the data to the 
model’s expectations and should be not significant (p>0.05).  
• The PSI is a measure of internal consistency of the scale, similar to a Cronbach’s 
alpha in classical test theory (30); PSI values above 0.7 are required for group use 
and above 0.8 for individual assessment.  
We tested for item bias across important person factors such as age group (<65, ≥65), 
gender, and diagnostic category (i.e. stroke, traumatic brain injury, anoxic brain injury, 
brain tumour, multiple sclerosis, spinal cord injury). As it was desirable to keep the 
original structure of the three Leg Activity measure scales, item removal would only be 
considered as a last resort to improve the fit. The items at risk of deletion were those 
exhibiting significant misfit, i.e., excessive residual values (> ± 2.5) and a p value 
significant at the 0.05 level, with a Bonferroni adjustment for multiple tests[24]. 
Unidimensionality was tested using Rasch principal components analysis of the residuals 
and the equating t test.  Unidimensionality of the scale is confirmed if significant t-test 
comparisons do not exceed 5% or if the lower bound of a binominal confidence interval 
computed for the number of significant t-tests overlaps the 5% cut-off point[25]. Finally, 
we followed the 10 quality indicators for evaluating the quality of reporting Rasch studies 
developed by the Rasch Special Interest Group of Outcome Measures in Rheumatology 
[26].  
 
Interpretability was addressed through the converting of the interval ‘logit’ scale 
produced by Rasch analysis into the ordinal scale structure of the original scale. This 
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allows interpretation of the ordinal scale structure in identifying true change as identified 
through the ‘logit’ or interval scale for this sample at any point on the scale. 
 
Feasibility was evaluated (Time 1) using a self-completed questionnaire administered 
following Leg Activity measure completion.  Patients and carers rated the timeliness, ease 
of use and relevance.   
 
Results 
In stage 1, results are presented for the initial 64 participants. In stage 2, the initial 64 
are combined with the additional 100 participants, with a total number of 164. 
 
Stage 1: results 
A total of 65 participants consented to involvement in stage 1, one patient subsequently 
refused clinical intervention and was excluded, 64 participants were therefore included 
in the prospective cohort.  Mean age was 51 (SD 17.4), 32 (50%) male.  The 
demographic characteristics of participants are described in Table 1. 
Table 1 Demographic characteristics of the study population stage 1 (n=64) 
 
The medians and interquartile ranges for the measures used at baseline, 1 day and 6 weeks 
are shown in Table 2.   
Table 2: Median and inter-quartile range (IQR) for the study measures 
 
The Leg Activity measure passive function, active function and impact scores were 
distributed over the full range of each subscale; passive function (0 to 36), active function 
(0 to 60) and impact (0 to 36).  In the active function scale, a complete range of scores 
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was produced, however a ceiling effect occurred with 23% (n=15) of scores for active 
function at the maximum point on the scale (i.e. totally unable to perform all items). 
Completion of the three subscales of Leg Activity measure was achieved by 62 (97%) of 
participants in 15 minutes or under.   
 
Internal consistency (time 1): Cronbach’s alpha was 0.86 for the Leg Activity measure 
passive function scale, 0.97 for active function and 0.87 for impact scale, demonstrating 
high internal consistency in each of the scales.   
 
Test re-test reliability: Quadratic weighted Kappa coefficients for the Leg Activity 
measure scale scores at time 1 and 2 were passive function 0.83 (Standard Error 0.076), 
active function 0.91 (Standard Error 0.076), and impact 0.82 (Standard Error 0.076).   
 
Item-level agreement ranged from 92% to 98%, and Quadratic weighted Kappa co-
efficients ranged from 0.68 to 0.95. The Kappa coefficients conformed to “substantial” 
or “almost perfect” criteria for all items [27].   
 
Construct validity: As expected a significant correlation was seen between change in 
the Leg Activity measure ‘passive function’ and Goal Attainment Scaling ‘T’ score at 6 
weeks (Rho -.350; p=0.013). A significant correlation was also identified as predicted 
between composite Modified Ashworth Scale and Leg Activity measure passive function 
at 6 weeks (Rho -.247; p=0.049). 
 
Psychometric evaluation the Leg Activity measure 
 
 20 
In keeping with the hypothesis, there was a significant correlation between the Leg 
Activity measure active function and the Rivermead Mobility Index at 6 weeks (Rho=-
.834; p=0.000) and 12 weeks (Rho=-.892; p=0.000) following intervention.  
 
In the Leg Activity measure impact scale, no correlation was seen as hypothesised 
between the Euro Quality of life 5 Dimensions. Correlations were seen between change 
in the impact scale and change in Modified Ashworth Scale at 6 weeks (Rho -.266; 
p=0.046) and 12 weeks (Rho -.276; p=0.037) as anticipated. 
 
Responsiveness: Significant differences were identified between responders and non-
responders according to Modified Ashworth Scale in the passive function scale at 6 weeks 
(p = 0.05) and 12 weeks (p = 0.007). A significant difference was also identified between 
responders and non-responders according to Goal Attainment Scaling at 12 weeks (p = 
0.049) for passive function. 
 
 For the active function scale a significant difference was identified between responders 
and non-responders according to Modified Ashworth Scale at 12 weeks (p = 0.002), but 
not at 6 weeks. A significant difference was not detected for the responder group 
according to goal, reflecting the smaller number of active function goals in this cohort. 
 
A significant difference was also identified between responders and non-responders 
according to Modified Ashworth Scale by the impact on quality-of-life scale at 6 weeks 
(p = 0.047) and 12 weeks (p = 0.039). 
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The passive function and impact scales of Leg Activity measure demonstrated significant 
(Friedman’s Test – Non-parametric ANOVA) change from baseline to 6 weeks and 12 
weeks (outcome) following spasticity intervention at 0.05 significance.  However 
significant changes were not seen for active function, which also corresponded with lack 
of change recorded by the Rivermead Mobility Index and reflected the smaller number of 
active function goals in this cohort. 
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Stage 2: results 
For the 100 additional participants mean age was 49 (SD 18.7), 56 (56%) male.  The 
demographic characteristics of additional participants are described in Table 3. 
Table 3 Demographic characteristics of the study population stage 2 (n=100) 
 
Principal Component Analyses 
Leg Activity measure Passive Scale 
A principal component analysis of the nine passive items showed evidence of two 
distinct factors with seven items loading very highly (i.e. > 0.80) on the first unrotated 
principal component (PC) and two items (Splint, Foot) with low loadings on the first 
unrotated principal component and high loadings (i.e. >.75) on the second. Varimax 
rotation produced a very similar pattern of loadings and this is illustrated in Figure 1 
(Passive) which plots the loadings of the nine passive items on the two rotated factors. 
Both the ‘splint’ and ‘foot’ items have clear clinical differences from the other items 
which are more directly focused on ease of personal care. 
  




Figure 1 Variamx rotation loadings for passive, active and impact scales 
 
 
Leg Activity measure Active Scale  
A principal component analysis of the 15 active function items suggested a strong 
general factor with the first component accounting for 75.5% of total variance and all 15 
items loading > 0.60 on the first unrotated component. The first two components 
accounted for 84% of total variance and were the only two components with 
eigenvalues > 1.0. Rotation of two factors resulted in poor evidence for two factors with 
9 out of 15 items loading > 0.40 on both factors.  
 
Leg Activity measure Quality of Life Scale 
A principal component analysis of the nine Quality of Life items of the Leg Activity 
measure revealed two components with eigenvalues > 1.0 that together accounted for 
66% of the total variance in responses. Varimax rotation produced good evidence for 
two factors one related to symptoms (e.g. Pain, Spasms) and one to social life (e.g. 
Activities, Social, Work) as illustrated in Figure 1 (impact) which plots the loadings of 
the nine passive items on the two rotated factors. From a real-life perspective symptoms 
and social and work life make logical sense in being different factors, both of which 
relate to quality of life. These factors again, have strong face validity and make clinical 
sense. 
Rasch analysis 
Structural validity was examined using adherence to the Rasch Partial Credit Model, once 
the appropriateness of application of the model had been confirmed.  




Leg Activity measure Passive Scale 
Analysis combining both samples (n=164) indicated reliability of the Leg Activity 
measure Passive by person separation index (PSI) of 0.74. However, overall fit to the 
Rasch model was unsatisfactory with 2 = 241.96 (18), p<0.00 (Table 4). Items with 
disordered thresholds were identified for; hygiene, splint application, wheelchair, 
hoisting, underwear, bed positioning and footwear.  These items were successfully 
rescored.  Overall fit to the Rasch model was still unsatisfactory and items for splint and 
foot were removed from the scale. This mirrored findings for the principal component 
analysis with both the ‘splint’ and ‘foot’ items having clinical differences from the other 
items which are more directly focused on ease of personal care (see Figure 2). Overall 
fit to the Rasch model was then satisfactory with 2 = 25.45 (21), p<0.23 (Table 4 and 
Figure 3). 
 
Figure 2 Leg Activity measure Passive Scale item threshold maps 
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Table 4 Leg Activity measure Passive function, Active function and Impact scale 
item fit and location (n=164) 
 
The person-item threshold distribution demonstrated a clear distribution of persons 
across the range of the scale (see Figure 3).  Similarly, a consistent distribution of items 
was also seen (see Figure 2).  
Figure 3 Leg Activity measure person-item threshold plots  
  
 
Leg Activity measure Active scale 
Again, combining both samples (n=164) indicated reliability of the Leg Activity 
measure Active by person separation index (PSI) of 0.95. However, overall fit to the 
Rasch model was unsatisfactory with 2 = 97.66 (30), p<0.00 (Table 4). Items with 
disordered thresholds were identified for; transfer car, indoor walking, turning, stairs, 
obstacles, walking over carpet, walking outdoors, walking over rough ground and 
walking half a mile.  These items were successfully rescored.   However, fit to the 
model could not be achieved through re-scoring items or their removal. Six super-items 
were produced using the Principal Components Analysis for reference. The items 
appeared to form a single scale with increasing difficulty along a continuum of the items 
(see Fig 2, Active) , which also corresponded to the clinically based prediction. Items 
were therefore placed into 6 super-items based on the PCA and clinical interpretation, 
maintaining the hierarchy of the items, with 1. turning, lying, 2. sitting, transfer chair 
and transfer car, 3. stand, sit to stand, forming the first three super-items; and 4. walking 
indoors and turning, 5. stairs, obstacles, walking over carpet, 6. walking outdoors, 
walking over rough ground and walking over half a mile forming the final three super-
items. These super-items make clinical sense with the resulting super-items representing 
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increasing difficulty from turning in bed and lying in item 1, to outdoor mobility and 
walking greater distances in item 6. Overall fit to the Rasch model was then generally 
satisfactory with 2 = 49.2 (36), p<0.07 (Table 4).  
 
Leg Activity measure Impact on Quality of Life 
Both samples combined (n=164), indicated reliability of the Leg Activity measure 
Impact scale by person separation index (PSI) of 0.85. However, overall fit to the Rasch 
model was unsatisfactory with 2 = 33.28 (18)/0.01, p<0.01 (Table 4). Based on the 
Rasch findings and those from the principal components analysis, two super-items were 
produced. The first super item included; pain, comfort, caring, spasms and range of 
movement. The second super-item included; mobility, activities, social activities and 
work activities. These super items again made clinical sense with the first super-item 
representing symptoms relating to quality of life and the second to functional activities 
and wider participation. Overall fit to the Rasch model was then generally satisfactory 
with 2 = 4.38 (4), p<0.36 (Table 4). 
 
Structural validity: Preliminary comparison of Rasch logits to ordinal scales 
The logits produced by the Rasch model were then converted back to the original 
ordinal scale structures as shown in Table 5 for Passive function, Table 6 for Active 
Function and Table 7 for Impact on quality-of-life.   
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Table 5 Conversion of raw Leg Activity measure scores to logits and then re-scored 
to the original scale (n=164) for the passive function scale. 
 
Table 6 Conversion of raw Leg Activity measure scores to logits and then re-scored 
to the original scale (n=164) for the active function scale. 
 
 
Table 7 Conversion of raw Leg Activity measure scores to logits and then re-scored 
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When converted back to the original structure all points on the original ordinal scales do 
not reflect a change on the interval Rasch logit scale, which is clearly demonstrated in 
the conversion.  Using the re-scored ordinal scale structure should allow a clinician to 
identify when real change has occurred on the original scale according to the interval 
level scale produced using the Rasch model. 
 
 
Feasibility: Ease of completion was rated as ‘Very easy’ to ‘Moderately easy’ by 91% 
(n=58) of patients or carers in the initial sample of 64 participants.  Completion of the 
Leg Activity measure was undertaken by 97% (n=62) of participants in 15 minutes or 
under.  Relevance of the measure was rated by 91% (n=58) of respondents as ‘Very 
relevant’ to ‘Moderately relevant’.   
  




This initial evaluation of the psychometric properties of the Leg Activity measure in 
relation to the COnsensus‐based Standards for the selection of health Measurement 
INstruments checklist and Medical Outcomes Trust Quality Criteria [9, 10], supports the 
measurement properties of the Leg Activity measure scales. Construct validity is 
supported, with confirmation of predicted correlations with comparison measures.  
Principal Components Analysis enabled exploration of the structure of each of the three 
scales. Items in each scale showed a relationship to each other, confirming that the scales 
again have acceptable construct validity for application in the clinical environment. 
 
On inspection of individual item-fit and individual person-fit statistics, a good fit to the 
Rasch Model was found but required sub-test analysis for the active and impact on quality 
of life scales.  Internal consistency and test-retest reliability, were excellent in the three 
Leg Activity measure scales.  Responsiveness was identified in the passive function and 
impact on quality-of-life function scales. In the active function scale, responsiveness was 
also demonstrated, but would benefit from further evaluation. The Leg Activity measure 
scales were feasible for patients to complete in a timely manner. Table 8 provides a 
summary of the psychometric properties. 
 
Table 8 Summary of Leg Activity measure psychometric properties. 
 
In the stage 1 study group (n=64), changes in passive function and active function scales 
mirrored the changes seen for goals in these areas or constructs. In the full cohort used 
(n=164), fewer active function goals were however set and therefore active function 
changes were seen in a smaller number of individuals. The conversion of logits back to 
Psychometric evaluation the Leg Activity measure 
 
 30 
the original format provides an indication for this population of real change at different 
points on the original scale.   
 
The Leg Activity measure is the only published self-report measure in the current 
literature that addresses passive and active function as well as impact on quality of life, 
of the paretic lower limb in a comprehensive manner.  The Leg Activity measure is 
designed for self-completion, making it potentially useful for patient and/or carer 
completion at a clinic or return by post following clinic visits with low clinician burden.  
The Leg Activity measure has also been used as the basis for structured interview 
undertaken at the clinic visit, as well as completed though telephone interview.  The 
findings presented here in the context of treatment for lower limb spasticity, provide 
initial psychometric support for its further testing and use.  
 
While no other measurement tool of this type is available for lower limb evaluation, a 
number of other tools have been developed and used in the context of upper limb 
spasticity [28]. The Arm Activity measure [29-31] was developed by our research team 
to address the need to measure improvements in arm passive and active function 
following spasticity treatment. The Leg Activity measure is the first tool to address these 
issues of patient reported functional outcome in the context of leg spasticity. The Leg 
Activity measure develops these concepts further than has currently been undertaken for 
arm spasticity in considering the impact of improvement in arm passive or active function 
on wider quality of life. 
 
Correlations were not seen between the Leg Activity measure Impact scale and Euro 
Quality of life 5 Dimensions. As expected, based on previous studies of botulinum toxin 
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intervention [32, 33], change in quality of life was not detected by Euro Quality of life 5 
Dimensions following botulinum toxin intervention in the leg, however significant 
changes were identified following treatment, by the Leg Activity measure Impact scale 
in this cohort at outcome compared with baseline, indicating it forms a sensitive condition 
specific measure of spasticity related quality-of-life in the leg. 
 
The authors recognise the following limitations to this study. 
Firstly, it is important for a patient reported measure such as Leg Activity measure to 
capture both passive and active function, which form separate domains. However due to 
the functional impairment of those requiring intervention for passive function limitation, 
a floor effect was seen in active function for 23% of respondents. However in this context 
this does not indicate a limitation of the measurement scale, but rather further justification 
to support the application of both scales. However in the study group, there were fewer 
individuals with active function goals and correspondingly fewer individuals changing as 
measured by the active function scale. 
 
Secondly, some items in the Leg Activity measure passive scale were identified with 
disordered thresholds.  These items were rescored by collapsing the number of response 
options, which resulted in ordered thresholds for all items. Once the items with disordered 
thresholds had been rescored, item bias was not identified for age, gender, aetiology or 
diagnosis.  The distribution of persons and items across the range of the scale show the 
ability of Leg Activity measure passive function to target the full range of function in this 
domain. Sub-test analysis was required to fit the active and impact of quality of life scales 
to the Rasch Partial Credit model. A good fit was then achieved. 
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Thirdly, a lower correlation was shown between Leg Activity measure and Modified 
Ashworth Scale. However, while we would expect there to be a relationship due to the 
intervention reducing spasticity (measured by Modified Ashworth Scale), the Leg 
Activity measure is measuring a different construct, that of activity (function), and so the 
relationship will not be perfect. 
 
Fourthly, further evaluation of responsiveness to look at minimally important clinical 
difference was not possible in this study. With the Rasch converted scale, any change in 
the Leg Activity measure scales should represent a meaningful difference and represents 
the approach taken in the current work to addressing this issue. However, in the future it 
would be helpful to test this using the Rasch converted scale. 
 
Despite these limitations, the study provides support for the Leg Activity measure as a 
valid, reliable and responsive tool for the evaluation of treatment in leg spasticity 
including condition specific quality-of-life. Ongoing evaluation, including additional 
exploration of Leg Activity measure scaling and measurement properties is underway.   
 
Conclusions 
This study demonstrated that the Leg Activity measure is a valid, reliable and responsive 
tool for the evaluation of treatment in leg spasticity, including a condition specific quality-
of-life. While further testing is valuable, the Leg Activity measure can be used in practice 
and research for evaluation of outcome and measurement of clinical improvements in 
functional performance in individuals with post-stroke and acquired brain injury 
spasticity.  
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Table 1 Demographic characteristics of the study population (n=64) 
  






Stroke 34 (53 %) 
Traumatic brain injury 10 (16 %) 
Anoxic brain injury 5   (8 %) 
Brain tumour 6 (9 %) 
Multiple Sclerosis 8 (13 %) 
Spinal cord injury 1 (1 %) 
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10.5 (5-15) 10.5 (5-15) 5 (2-11) 
Leg Activity 
measure Active 
50 (25.5-59) 51.5 (26.2-59) 51 (24-59) 
Leg Activity 
measure Impact 
21 (13.5-25.5) 21 (15.2-27) 13.5 (7.2-19.7) 
Rivermead 
Mobility Index 
1 (0-7.7) - 2.5 (2-7) 
EQ-5D (Health 
scale 0-100) 




13 (8-18) - 7 (4-12) 
Goal Attainment 
Scaling 
37.6 (31.4-37.6) - 50 (42.5-50) 
Key: IQR - inter-quartile range 
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Table 3 Demographic characteristics of the study population (n=100) 
  






Stroke 49 (49 %) 
Traumatic brain injury 34 (34 %) 
Anoxic brain injury 4 (4 %) 
Brain tumour/Infection 5 (5 %) 
Multiple Sclerosis 8 (8 %) 
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Location mean  Fit residual  
Mean 




-0.46 (2.53) -1.09 (1.11) -0.23 (1.23) 241.96 (18)/0.00 0.74 Yes 0% 
Passive (9 items 
rescored*)  
Analysis 2 
0.00 (0.40) -0.36 (2.61)  -1.48 (1.46) -0.24 (1.26) 190.65 (18)/0.00 0.76 Yes 3.66% 
Passive (7 items)  
Analysis 3 
 
0.00 (0.55) 0.12 (0.82)  -1.74 (1.93)  -0.51 (1.54)  25.45 (21)/0.23 0.83 Yes 7.32% (CI 4 – 
10%) 
Active (15 items) 
Analysis 1  
0.00 (1.14) -0.27 (2.06) 1.80 (2.85) -0.38 (1.21)  97.66 (30) 0.00 0.95 No 32% 
Active (6 super items) 
Analysis 2  
0.00 (1.30) -0.46 (1.83)  1.32 (2.10)  -0.26 (0.82)  49.2 (36)/0.07 0.93 Yes 3.85% 
Impact (9 items)  0.00 (0.50) 0.54 (1.89)  0.06 (1.11) -0.46 (1.64)  33.28 (18)/0.01 0.85 No 13% 
Impact (2 super items)  0.00 (0.23) 0.30 (0.45) 0.00 (0.57)  -0.44 (0.87)  4.38 (4)/ 0.36 0.85 Yes 1.5% 
Psychometric evaluation the Leg Activity measure 
 
 41 
*Rescored item categories are indicated in figure 3; 7 item passive function threshold map0 
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Table 5 Conversion of raw Leg Activity measure scores to logits and then re-scored 
to the original scale (n=164) for the passive function scale. 
Ordinal Measure  
Leg Activity 
measure Raw score 
Interval Measure 
 
 Logits (Rasch Location) Re-score to 36 
0 -3.304 0 
1 -2.647 3 
2 -2.224 4 
3 -1.95 6 
4 -1.746 6 
5 -1.58 7 
6 -1.44 8 
7 -1.316 8 
8 -1.204 9 
9 -1.101 9 
10 -1.004 10 
11 -0.912 10 
12 -0.824 10 
13 -0.738 11 
14 -0.656 11 
15 -0.574 11 
16 -0.494 12 
17 -0.413 12 
18 -0.332 12 
19 -0.25 13 
20 -0.164 13 
21 -0.072 13 
22 0.026 14 
23 0.134 14 
24 0.257 15 
25 0.397 15 
26 0.559 16 
27 0.748 17 
28 0.966 18 
29 1.221 19 
30 1.519 20 
31 1.873 21 
32 2.294 23 
33 2.799 25 
34 3.428 28 
35 4.27 31 
36 5.399 36 
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Table 6 Conversion of raw Leg Activity measure scores to logits and then re-scored 
to the original scale (n=164) for the active function scale. 
Ordinal Measure  
Leg Activity 
measure Raw score 
Interval Measure 
 
 Logits (Rasch Location) Re-score to 49 
0 -3.515 0 
1 -3.515 1 
2 -2.805 5 
3 -2.6 7 
4 -2.431 7 
5 -2.279 8 
6 -1.836 11 
7 -1.836 11 
8 -1.836 11 
9 -1.68 12 
10 -1.519 13 
11 -1.354 13 
12 -1.19 14 
13 -1.031 15 
14 -0.881 16 
15 -0.741 17 
16 -0.611 18 
17 -0.49 18 
18 -0.49 18 
19 -0.276 19 
20 -0.179 20 
21 -0.088 21 
22 -0.001 21 
23 0.082 21 
24 0.163 22 
25 0.242 22 
26 0.321 23 
27 0.4 23 
28 0.48 24 
29 0.48 24 
30 0.65 25 
31 0.742 25 
32 0.742 25 
33 0.742 25 
34 1.045 27 
35 1.153 27 
36 1.264 28 
37 1.376 29 
38 1.492 29 
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39 1.612 30 
40 1.739 31 
41 1.873 31 
42 2.015 32 
43 2.163 33 
44 2.32 34 
45 2.32 34 
46 2.69 36 
47 2.945 37 
48 3.347 40 
49 3.979 43 
The score range could only be converted back to the range represented in these data, 
which was up to 49 (rather than the original 60). This results from the ceiling effect for 
the active function scale (see person-item distribution figure 3). 
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Table 7 Conversion of raw Leg Activity measure scores to logits and then re-scored 
to the original scale (n=164) for the impact (quality of life) scale. 
Ordinal Measure 
Leg Activity 
measure Raw score 
Interval Measure 
 
 Logits (Rasch Location) Re-score to 36 
0 -2.768 0 
1 -1.488 8 
2 -0.973 11 
3 -0.766 12 
4 -0.668 12 
5 -0.603 13 
6 -0.551 13 
7 -0.508 13 
8 -0.468 14 
9 -0.432 14 
10 -0.4 14 
11 -0.367 14 
12 -0.333 14 
13 -0.302 15 
14 -0.268 15 
15 -0.235 15 
16 -0.202 15 
17 -0.166 15 
18 -0.132 16 
19 -0.096 16 
20 -0.06 16 
21 -0.022 16 
22 0.017 17 
23 0.056 17 
24 0.098 17 
25 0.144 17 
26 0.194 18 
27 0.251 18 
28 0.318 18 
29 0.399 19 
30 0.507 19 
31 0.664 20 
32 0.913 22 
33 1.288 24 
34 1.785 27 
35 2.437 31 
36 3.291 36 
 
 




Table 8 Summary of Leg Activity measure psychometric properties. 2 
Attribute Criteria Evaluation 
Validity Face Confirmed during pilot testing. 
Content Aim; population and target concepts: The Leg Activity measure is designed to provide a low burden measure 
of difficulty in active and passive function and impact on quality of life for patients undergoing spasticity 
management in the leg.   
Item selection and reduction; Item selection used a systematic review and patient selected items followed by 
Delphi consensus process with specialist clinicians and confirmed with a patient and carer advisory group.  
Interpretability of items: Understanding was confirmed during pilot testing [9]. 
Criterion-
related 
No accepted gold standard measure for comparison currently exists for passive and active leg function.   
The impact on quality of life scale, was not correlated due to apparent lack of sensitivity to change of EQ-5D 





Convergent: The passive function scale correlated with change in spasticity and goal outcome, active function 
was correlated with the Rivermead Mobility Index (Rho -0.25) and Impact on quality-of-life was not correlated 
with EQ-5D, but was correlated with changes in spasticity all as predicted. 
Divergent: The passive function scale did not significantly correlate with the Rivermead Mobility Index or EQ-
5D. The active function subscale was not correlated with EQ-5D. The impact scale was not correlated with the 
Rivermead Mobility Index. 




Kappa  0.70 
[9]) 
Total Quadratic Weighted Kappa coefficients for the passive function scale was 0.83, active function scale was 
0.91 and impact scale was 0.82.  
  3 
Psychometric evaluation the Leg Activity measure 
 
 48 
Responsiveness  A significant difference was identified between responders and non-responders using the Leg Activity measure 
passive function, active function and the ‘impact on quality of life’ scales. 
 
Interpretability  Following evaluation of conformity to the Rasch model a logit conversion of the original ordinal scale has 
been produced for the passive function scale. 
Floor/ceiling 
effects 
 No significant floor or ceiling effects in the passive function or impact scales was identified, but a 23% 






Time for completion of Leg Activity measure was 15 minutes or under in 97% of patients in this analysis. 
Ease of use  Ease of completion was rated as very easy, easy or moderate by 91 % of patients or carers.   
Relevance Relevance of the overall scale was rated by 91% of respondents as very relevant to moderately relevant.   
Alternative modes of administration Leg Activity measure has been administered during testing as a self-completion questionnaire or as an 
interview (face-to-face or over the telephone).   
Cultural and language adaptations None currently available 
4 






Figure 1 Variamx rotation loadings for passive, active and impact scales 2 
Passive    Active    Impact 3 
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Figure 2 Leg Activity measure Passive Scale item threshold maps 7 
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